ATE474853T1 - Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren - Google Patents

Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren

Info

Publication number
ATE474853T1
ATE474853T1 AT06789294T AT06789294T ATE474853T1 AT E474853 T1 ATE474853 T1 AT E474853T1 AT 06789294 T AT06789294 T AT 06789294T AT 06789294 T AT06789294 T AT 06789294T AT E474853 T1 ATE474853 T1 AT E474853T1
Authority
AT
Austria
Prior art keywords
immunoglobulin
cells
expression
apoptosis
inhibitor
Prior art date
Application number
AT06789294T
Other languages
English (en)
Inventor
Roland Buelow
Josef Platzer
Original Assignee
Therapeutic Human Polyclonals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals filed Critical Therapeutic Human Polyclonals
Application granted granted Critical
Publication of ATE474853T1 publication Critical patent/ATE474853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06789294T 2005-08-03 2006-08-02 Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren ATE474853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70530505P 2005-08-03 2005-08-03
PCT/US2006/030250 WO2007019223A1 (en) 2005-08-03 2006-08-02 Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin

Publications (1)

Publication Number Publication Date
ATE474853T1 true ATE474853T1 (de) 2010-08-15

Family

ID=37309396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06789294T ATE474853T1 (de) 2005-08-03 2006-08-02 Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren

Country Status (9)

Country Link
US (3) US7919672B2 (de)
EP (1) EP1910418B1 (de)
JP (1) JP5188969B2 (de)
CN (3) CN103710371B (de)
AT (1) ATE474853T1 (de)
CA (1) CA2616069C (de)
DE (1) DE602006015653D1 (de)
ES (1) ES2347979T3 (de)
WO (1) WO2007019223A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
US20080227688A1 (en) * 2007-03-13 2008-09-18 Johnston Randal N Inhibition of viral replication
JP5827127B2 (ja) * 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
BR112014029417B1 (pt) * 2012-05-25 2023-03-07 Cellectis Método ex vivo para a preparação de células t para imunoterapia
AU2014370516B9 (en) 2013-12-24 2021-07-29 Kling Biotherapeutics B.V. Ex vivo antibody production
CN106413393A (zh) * 2014-03-21 2017-02-15 通用医疗公司 制造必需脂肪酸的非人转基因动物及其用途
EP3957738A1 (de) * 2015-03-04 2022-02-23 IGM Biosciences, Inc. Cd20-bindende moleküle und verwendungen davon
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
SG11201802698XA (en) * 2015-10-29 2018-05-30 Hoffmann La Roche Transgenic rabbit with common light chain
KR102483193B1 (ko) * 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
CN106480090B (zh) * 2016-10-08 2020-05-12 杭州电子科技大学 一种促进细胞移植和基因表达的转基因载体系统及其应用
GB201704417D0 (en) 2017-03-20 2017-05-03 Univ Copenhagen Improved li vaccine adjuvant
EP3731864A1 (de) 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anti-vegf-antikörper und verfahren zur verwendung
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
KR20260026086A (ko) 2023-06-21 2026-02-25 에프. 호프만-라 로슈 아게 Fap 표적화 림포톡신 베타 수용체 작용제를 이용한 조합 요법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010101647A (ko) * 1999-01-25 2001-11-14 메리 이. 보울러 폴리사카라이드 섬유
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20060200871A1 (en) * 2002-10-21 2006-09-07 Van Ness Brian G Transgenic non-human animals with expanded mature b cell and plasma cell populations

Also Published As

Publication number Publication date
JP2009502203A (ja) 2009-01-29
US20070033661A1 (en) 2007-02-08
CA2616069C (en) 2018-07-31
US7919672B2 (en) 2011-04-05
EP1910418A1 (de) 2008-04-16
CN103710371B (zh) 2017-03-01
WO2007019223A1 (en) 2007-02-15
CN101263158B (zh) 2011-12-28
CA2616069A1 (en) 2007-02-15
CN102443058A (zh) 2012-05-09
JP5188969B2 (ja) 2013-04-24
ES2347979T3 (es) 2010-11-26
US20130102072A1 (en) 2013-04-25
US20110219465A1 (en) 2011-09-08
CN101263158A (zh) 2008-09-10
DE602006015653D1 (de) 2010-09-02
EP1910418B1 (de) 2010-07-21
US8354568B2 (en) 2013-01-15
CN103710371A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
ATE474853T1 (de) Unterdrückung der b-zell apoptose in transgenen tieren die humanisierte immunglobulingene exprimieren
IL202302A (en) Methods for producing non-human germ cells having an inactivated ig locus, transgenic animals comprising same and monoclonal antibodies produced therein
MX355726B (es) Ratones transgenicos que expresan moleculas quimericas del complejo mayor de histocompatibilidad (cmh) clase ii.
MX2018005389A (es) Animales no humanos que tienen un gen 3 de activacion linfocitaria humanizado.
MXPA06000562A (es) Loci de inmunoglobulina humanizada.
PH12016500342A1 (en) Non-human animals having a humanized signal-regulatory protein gene
WO2007048077A3 (en) Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
PE20120551A1 (es) Anticuerpos contra la angiopoyetina 2 humana
SG10201408500RA (en) Antibody producing non-human mammals
SG158158A1 (en) Glp-1 agonists, compositions, methods and uses
MY164836A (en) Genetically modified major histocompatibility complex mice
MX2019002256A (es) Animales transgenicos no humanos que producen anticuerpos modificados solo de cadena pesada.
EP1573314A4 (de) Menschliches cd20 exprimierendetransgene mäuse
NZ759163A (en) Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
WO2007117410A3 (en) Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
NZ702943A (en) Humanized il-7 rodents
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2006117699A3 (en) Transgenic animals and methods of making recombinant antibodies
MX344856B (es) Dsarn como agente de control de insectos.
WO2008074880A3 (en) Transgenic animal model
TW200518669A (en) Animal model for protease activity and liver damage
ZA200707905B (en) Drought-resistant plants
ATE458403T1 (de) Transgene mäuse, die prkag3 exprimieren
SG142293A1 (en) Method for producing anti-idiotypic antibodies
WO2004072115A3 (en) Suppression of endogenous immunoglobulin expression in transgenic non-human animals expressing humanized or human antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties